Abstract:Diagnosis of malignant pleural effusion (MPE) is made by cytological examination of pleural fluid or histological examination of pleural tissue from biopsy. Unfortunately, detection of malignancy using cytology has an overall sensitivity of 50%, and is dependent upon tumor load, volume of fluid assessed, and cytopathologist experience. The diagnostic yield of pleural fluid cytology is also compromised by low abundance of tumor cells or when morphology is obscured by inflammation or reactive mesothelial cells. A reliable molecular marker that may complement fluid cytology for the diagnosis of malignant pleural effusion is needed. The purpose of this study was to establish a molecular diagnostic approach based on pleural effusion cell-free DNA methylation analysis for the differential diagnosis of malignant pleural effusion and benign pleural effusion. This was a blind, prospective case–control biomarker study. We recruited 104 patients with pleural effusion for the study. We collected pleural fluid from patients with: MPE (n = 48), indeterminate pleural effusion in subjects with known malignancy or IPE (n = 28), and benign PE (n = 28), and performed the Sentinel-MPE liquid biopsy assay. The methylation level of Sentinel-MPE was markedly higher in the MPE samples compared to BPE control samples ( p < 0.0001) and the same tendency was observed relative to IPE ( p = 0.004). We also noted that the methylation signal was significantly higher in IPE relative to BPE ( p < 0.001). We also assessed the diagnostic efficiency of the Sentinel-MPE test by performing receiver operating characteristic analysis (ROC). For the ROC analysis we combined the malignant and indeterminate pleural effusion groups (n = 76) and compared against the benign group (n = 28). The detection sensitivity and specificity of the Sentinel-MPE test was high (AUC = 0.912). The Sentinel-MPE appears to have better performance characteristics than cytology analysis. However, combining Sentinel-MPE with cytology analysis could be an even more effective approach for the diagnosis of MPE. The Sentinel-MPE test can discriminate between BPE and MPE. The Sentinel-MPE liquid biopsy test can detect aberrant DNA in several different tumor types. The Sentinel-MPE test can be a complementary tool to cytology in the diagnosis of MPE.

EGFR mutations in malignant pleural effusions from lung cancer

Comparative Study of EGFR Mutations Detected in Malignant Pleural Effusion, Plasma and Tumor Tissue in Patients with Adenocarcinoma of the Lung

Value of Malignant Pleural Effusion Supernatants (mpes) in Epidermal Growth Factor Receptor (EGFR) Mutation Detection of Patients with Advanced Lung Adenocarcinoma (ADC).

Malignant Pleural Effusion Supernatants Are Substitutes for Metastatic Pleural Tumor Tissues in EGFR Mutation Test in Patients with Advanced Lung Adenocarcinoma.

Relationship Between Mutations of Epidermal Growth Factor Receptor in the Plasma and Pleural Effusion and Responses to Gefitinib in Advanced Pretreated Non-Small Cell Lung Cancer

Prediction of Epidermal Growth Factor Receptor Mutations in the Plasma/pleural Effusion to Efficacy of Gefitinib Treatment in Advanced Non-Small Cell Lung Cancer.

Detection of EGFR Gene Mutation Status from Pleural Effusions and Other Body Fluid Specimens in Patients with Lung Adenocarcinoma

Pleural Effusion As a Substitute for Tumor Tissue in Detecting EGFR/ALK Mutations in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Malignant Pleural Effusion Cell Blocks Are Substitutes for Tissue in EML4‐ALK Rearrangement Detection in Patients with Advanced Non‐small‐cell Lung Cancer

Clinical impact of pleural fluid carcinoembryonic antigen on therapeutic strategy and efficacy in lung adenocarcinoma patients with malignant pleural effusion

Genome-wide Microrna Expression Profiling in Malignant Pleural Effusion to Identify a Ten-Microrna Signature.

Cell-free DNA methylation analysis as a marker of malignancy in pleural fluid

Comparison of Epidermal Growth Factor Receptor Gene Mutations Identified Using Pleural Effusion and Primary Tumor Tissue Samples in Non-Small Cell Lung Cancer.

Diagnostic Value of Pleural Effusion for the Detection of EGFR in NSCLC: a Meta-Analysis

Liquid Biopsies Using Pleural Effusion-Derived Exosomal DNA in Advanced Lung Adenocarcinoma.

Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients

Malignant pleural effusion supernatant is an alternative liquid biopsy specimen for comprehensive mutational profiling

A Multicenter Real-World Study of Tumor-Derived DNA from Pleural Effusion Supernatant in Genomic Profiling of Advanced Lung Cancer.

Molecular Profiling of Lung Adenocarcinoma Using Pleural Effusion Specimens.

Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients

Gene Alterations in Paired Supernatants and Precipitates from Malignant Pleural Effusions of Non-Squamous Non-Small Cell Lung Cancer